- In the HBV003 trial, 67% of participants had HBsAg
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
On 6ix: 6ix.com/news/barinthus-bios-vtp-300-trials-demonstrate-ability-achieve-undetectable-hbsag-levels
Arbutus Biopharma Corporation on 6ix
Earlier from Arbutus Biopharma
- Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
- Arbutus to Participate in Jefferies Global Healthcare Conference
- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
Later from Arbutus Biopharma
- Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
- Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Follow Arbutus Biopharma into a list and get an email when it puts out news.
Follow Arbutus Biopharma